相似文献
1
Raynaud's phenomenon induced by sulphasalazine.
Postgrad Med J. 1980 Feb;56(652):106-7. doi: 10.1136/pgmj.56.652.106.
2
Raynaud's phenomenon induced by sulphasalazine in a case of chronic ulcerative colitis.
J Assoc Physicians India. 1984 Apr;32(4):370.
3
Chemotherapy-induced Raynaud's phenomenon.
Cleve Clin J Med. 1994 May-Jun;61(3):195-9. doi: 10.3949/ccjm.61.3.195.
4
Raynaud's phenomenon of the nipple associated with labetalol use.
J Hum Lact. 2013 Feb;29(1):17-9. doi: 10.1177/0890334412467509. Epub 2012 Dec 4.
5
Raynaud's phenomenon in infertile women treated with bromocriptine.
Fertil Steril. 1987 Nov;48(5):877-9. doi: 10.1016/s0015-0282(16)59548-x.
6
[Raynaud's phenomenon after chemotherapy. Apropos of 3 cases].
Ann Dermatol Venereol. 1985;112(2):151-5.
7
Raynaud's phenomenon in hypothyroidism.
Angiology. 1976 Jan;27(1):19-25. doi: 10.1177/000331977602700104.
8
[Methylphenidate and secondary Raynaud's phenomenon].
Semergen. 2013 Sep;39(6):330-4. doi: 10.1016/j.semerg.2012.07.011. Epub 2012 Nov 4.
9
Laser Doppler-recorded venoarteriolar reflex in Raynaud's phenomenon.
Auton Neurosci. 2004 Nov 30;116(1-2):62-8. doi: 10.1016/j.autneu.2004.08.012.
10
[Validity of plethysmography and the digital temperature recovery test in the diagnosis of primary and occupational Raynaud's phenomenon].
Clin Invest Med. 1987 Mar;10(2):96-102.
引用本文的文献
1
Raynaud's Phenomenon: Reviewing the Pathophysiology and Management Strategies.
Cureus. 2022 Jan 28;14(1):e21681. doi: 10.7759/cureus.21681. eCollection 2022 Jan.
2
Secukinumab-induced Raynaud's phenomenon: first report in the literature.
Ther Adv Drug Saf. 2020 Feb 22;11:2042098620905976. doi: 10.1177/2042098620905976. eCollection 2020.
3
Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.
Br J Clin Pharmacol. 2016 Jul;82(1):6-16. doi: 10.1111/bcp.12912. Epub 2016 Apr 7.
4
Juvenile rheumatoid arthritis: therapeutic perspectives.
Paediatr Drugs. 2002;4(5):335-48. doi: 10.2165/00128072-200204050-00006.
5
Comparative tolerability of treatments for inflammatory bowel disease.
Drug Saf. 2000 Nov;23(5):429-48. doi: 10.2165/00002018-200023050-00006.
6
Sulfasalazine. Adverse effects and desensitization.
Dig Dis Sci. 1983 Sep;28(9):833-42. doi: 10.1007/BF01296907.
7
Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.
Drug Saf. 1991 May-Jun;6(3):192-219. doi: 10.2165/00002018-199106030-00005.
本文引用的文献
1
LUPUS ERYTHEMATOSUS CELL PHENOMENON IN PATIENTS WITH CHRONIC ULCERATIVE COLITIS.
Gut. 1965 Feb;6(1):39-47. doi: 10.1136/gut.6.1.39.
2
Drug-induced lupus syndromes.
Mayo Clin Proc. 1969 Sep;44(9):664-81.
3
Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.
N Engl J Med. 1973 Sep 6;289(10):491-5. doi: 10.1056/NEJM197309062891001.
4
Sulphasalazine-induced lupus syndrome in ulcerative colitis.
Br Med J. 1977 Nov 5;2(6096):1188-9. doi: 10.1136/bmj.2.6096.1188.
Zotero 插件